EQT Acquires Mabtech from IK Partners and Mérieux Equity Partners
January 9, 2024
EQT, via its newly launched EQT Healthcare Growth Strategy, is acquiring Swedish immunoassay specialist Mabtech AB from IK Partners and Mérieux Equity Partners. Mabtech, a developer and manufacturer of antibodies, kits and readers used in vaccine, infectious disease and oncology research, will be supported by EQT to expand its product portfolio and accelerate geographic growth, particularly in the US. The transaction is subject to customary regulatory approvals and financial terms were not disclosed.
- Buyers
- EQT, EQT Healthcare Growth Strategy
- Targets
- Mabtech AB
- Sellers
- IK Small Cap II Fund (IK Partners), Mérieux Participations 3 (Mérieux Equity Partners)
- Industry
- Biotechnology
- Location
- Stockholm, Sweden
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
EQT Acquires Intertek in $14.5 Billion Deal
June 18, 2026
Professional Services
EQT has agreed to acquire Intertek, a U.K.-based product testing, inspection, and certification company, in a deal valued at about £10.9 billion ($14.5 billion) including debt. The offer values Intertek’s equity at £9.5 billion and includes £61.08 per share in cash and dividend consideration.
-
EQT Private Equity Acquires SPT Labtech from Battery Ventures for GBP 650 million
June 22, 2022
Medical Devices
EQT Private Equity (EQT IX) has agreed to acquire SPT Labtech, a UK-based designer and manufacturer of automated liquid handling, sample preparation and consumables for life science research, from Battery Ventures for GBP 650 million. EQT will support SPT's next phase of growth by accelerating product innovation, scaling its Cryo-EM sample preparation business and expanding into new geographies and end markets; the transaction is expected to close in Q3 2022.
-
IK Investment Partners Acquires Mabtech
December 5, 2019
Biotechnology
IK Investment Partners’ IK Small Cap II Fund has agreed to acquire a majority stake in Mabtech AB, a Stockholm-based specialist in immune monitoring and developer of monoclonal antibodies, ELISpot/FluoroSpot kits and the IRIS reader. Mérieux Equity Partners takes a minority stake alongside IK, founders and management remain invested, and EQT Credit provided senior secured (unitranche) financing to support the transaction.
-
EQT Acquires Majority Stake in Ellab from IK Investment Partners
August 7, 2019
Medical Devices
EQT Mid Market Europe has agreed to acquire a majority interest in Ellab A/S from the IK VIII Fund (advised by IK Investment Partners). EQT will partner with Ellab's management, which will retain a minority stake, to accelerate global growth by expanding R&D, enhancing the go-to-market model in the US and Europe, and growing the company's as-a-service offerings.
-
Discovery Life Sciences Acquires QualTek Molecular Laboratories
May 5, 2019
Healthcare Services
Discovery Life Sciences (based in Huntsville, Alabama) has acquired QualTek Molecular Laboratories, a provider of CAP/CLIA-accredited and GLP-capable immunohistochemistry (IHC) laboratories in California and Pennsylvania. The acquisition expands Discovery's histopathology and IHC assay development capabilities and integrates QualTek's services with Discovery's biospecimen, sequencing, flow cytometry and multiomic annotation offerings to accelerate biomarker validation and drug/diagnostic development.
-
EQT Invests in MHC Asia Holdings (Healthcare Benefits Administrator)
April 1, 2019
Healthcare Services
EQT Mid Market Asia III Fund has made a strategic investment in MHC Asia Holdings Pte. Ltd., a Singapore-headquartered healthcare benefits administrator serving insurers and corporate clients across Southeast Asia. The investment will support MHC's regional expansion, further development of its technology and analytics capabilities, and growth of its client portfolio.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.